ArticleBMC infectious diseases2026
Characterization of multiple herpes viremia via next-generation sequencing in patients with lower respiratory tract infections: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLower respiratory tract infections (LRTIs) are a leading cause of the substantial morbidity and mortality associated with severe pneumonia. Herpesviruses (HHVs) frequently reactivate during critical illness, but their bronchoalveolar lavage fluid (BALF) coinfection patterns and clinical correlates remain incompletely defined.
methodsA retrospective cohort study was conducted among hospitalized adults with suspected LRTIs who underwent BALF next-generation sequencing (NGS) at the Yunnan First People’s Hospital between November 2024 and May 2025. Two analytical workflows were evaluated, namely metagenomic DNA sequencing (mNGS-DNA) and a targeted NGS (tNGS) panel, including 289 and 675 patients, respectively. Participants were subsequently classified into a herpesvirus-detected (HD) group and a non-herpesvirus-detected group (non-HD).
resultsIn mNGS-DNA, detection frequencies were EBV 17.30%, CMV 14.88%, HHV-7 9.00%, HSV-1 8.30%, HHV-6 4.15%, and VZV 0.34%, single- and multi-virus positivity were 22.84% and 11.76%. In tNGS, the corresponding values were 17.93%, 12.00%, 7.11%, 10.07%, 2.96%, and 0.30%, single- and multi-virus positivity were 24.44% and 15.11%. HD patients were older and more likely to have severe pneumonia in both cohorts (P < 0.0001). Bacteria were the predominant pathogens in the patients with suspected LRTIs, followed by viruses and fungi. In matched BALF subsets, sequencing outperformed culture for bacterial detection (mNGS-DNA 37.90% vs. 20.56%; tNGS 87.45% vs. 13.45%; all P < 0.001), underscoring the complementary yield over conventional culture methods. HHVs exhibited the highest co-infection rates with pathogens such as Stenotrophomonas maltophilia, Klebsiella pneumoniae, and Candida albicans.
conclusionsIn BALF from hospitalized LRTI patients, EBV and CMV predominate among herpesviruses, with HHV-7 a frequent coinfection partner. These findings underscore the need for prospective studies to define the prognostic impact of HHV coinfections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.